Development rate of chronic kidney disease in hepatitis C virus patients with advanced fibrosis after interferon therapy

Yasuji Arase, Fumitaka Suzuki, Yusuke Kawamura, Yoshiyuki Suzuki, Masahiro Kobayashi, Naoki Matsumoto, Norio Akuta, Hitomi Sezaki, Tetsuya Hosaka, Kyoko Ogawa, Norihiro Imai, Yuya Seko, Satoshi Saito, Kenji Ikeda, Mariko Kobayashi, Hiromitsu Kumada

Research output: Contribution to journalArticlepeer-review

35 Citations (Scopus)

Abstract

Aim: The aim of this retrospective cohort study is to assess the development incidence and predictive factors for chronic kidney disease (CKD) after the termination of interferon therapy in hepatitis C virus (HCV) positive Japanese patients with liver cirrhosis. Methods: A total of 650 HCV positive, liver cirrhotic patients who were treated with interferon and showed an estimated glomerular filtration rate (eGFR) of ≥60mL/min per 1.73m2 after the termination of interferon therapy were enrolled. CKD was defined as an eGFR of <60mL/min per 1.73m2. End-stage-CKD was defined as an eGFR of <15mL/min/1.73m2. The primary goal is the new development of CKD and end-stage-CKD. Results: Eighty-five patients developed CKD, and six patients progressed to end-stage-CKD. The development rate of CKD was 5.2% at the 5th year, 14.5% at the 10th year and 30.6% at the 15th year. Multivariate Cox proportional hazards analysis showed that CKD occurred when patients had age increments of 10years (hazard ratio: 2.32; 95% confidence interval [CI] 1.61-3.35; P<0.001), eGFR decrements of 10mL/min per 1.73m2 (hazard ratio: 1.66; 95% CI 1.27-2.16; P<0.001), hypertension (hazard ratio: 2.00; 95% CI 1.13-3.53; P=0.017), diabetes (hazard ratio: 1.79; 95% CI 1.02-3.14; P=0.042), and non-clearance of HCV (hazard ratio: 2.67; 95% CI 1.34-5.32; P=0.005). The development rate of end-stage-CKD was 0.4% at the 5th year, 1.6% at the 10th year and 2.8% at the 15th year. Conclusions: The annual incidence for CKD among cirrhotic patients with HCV was determined to be about 1.0-1.5%. In addition, the annual incidence for end-stage-CKD is one order of magnitude lower than that of CKD.

Original languageEnglish
Pages (from-to)946-954
Number of pages9
JournalHepatology Research
Volume41
Issue number10
DOIs
Publication statusPublished - Oct 2011
Externally publishedYes

Keywords

  • Chronic kidney disease
  • Hepatitis C virus
  • Liver cirrhosis

Fingerprint

Dive into the research topics of 'Development rate of chronic kidney disease in hepatitis C virus patients with advanced fibrosis after interferon therapy'. Together they form a unique fingerprint.

Cite this